-
(
OkuiMYamamichiTAsakawaA, et al
Prognostic significance of neutrophil-lymphocyte ratios in large cell neuroendocrine carcinoma. Gen Thorac Cardiovasc Surg
2017; 65: 633–639.28766133)
OkuiMYamamichiTAsakawaA, et al
Prognostic significance of neutrophil-lymphocyte ratios in large cell neuroendocrine carcinoma. Gen Thorac Cardiovasc Surg
2017; 65: 633–639.28766133
OkuiMYamamichiTAsakawaA, et al
Prognostic significance of neutrophil-lymphocyte ratios in large cell neuroendocrine carcinoma. Gen Thorac Cardiovasc Surg
2017; 65: 633–639.28766133,
OkuiMYamamichiTAsakawaA, et al
Prognostic significance of neutrophil-lymphocyte ratios in large cell neuroendocrine carcinoma. Gen Thorac Cardiovasc Surg
2017; 65: 633–639.28766133
-
D.
Kazandjian,
Y.
Gong,
P.
Keegan,
R.
Pazdur,
G.
Blumenthal
(2019)
Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung Cancer.
JAMA oncology
-
(
WangXTengFKongL, et al
Pretreatment neutrophil-to-lymphocyte ratio as a survival predictor for small-cell lung cancer. Onco Targets Ther
2016; 9: 5761–5770.27703374)
WangXTengFKongL, et al
Pretreatment neutrophil-to-lymphocyte ratio as a survival predictor for small-cell lung cancer. Onco Targets Ther
2016; 9: 5761–5770.27703374
WangXTengFKongL, et al
Pretreatment neutrophil-to-lymphocyte ratio as a survival predictor for small-cell lung cancer. Onco Targets Ther
2016; 9: 5761–5770.27703374,
WangXTengFKongL, et al
Pretreatment neutrophil-to-lymphocyte ratio as a survival predictor for small-cell lung cancer. Onco Targets Ther
2016; 9: 5761–5770.27703374
-
M.
Deng,
Xuelei
Ma,
X.
Liang,
Chenjing
Zhu,
Manni
Wang
(2017)
Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
Oncotarget, 8
-
(
MeyersDEStukalinIVallerandIA, et al
The lung immune prognostic index discriminates survival outcomes in patients with solid tumors treated with immune checkpoint inhibitors. Cancers (Basel)
2019; 11: 1713.)
MeyersDEStukalinIVallerandIA, et al
The lung immune prognostic index discriminates survival outcomes in patients with solid tumors treated with immune checkpoint inhibitors. Cancers (Basel)
2019; 11: 1713.
MeyersDEStukalinIVallerandIA, et al
The lung immune prognostic index discriminates survival outcomes in patients with solid tumors treated with immune checkpoint inhibitors. Cancers (Basel)
2019; 11: 1713.,
MeyersDEStukalinIVallerandIA, et al
The lung immune prognostic index discriminates survival outcomes in patients with solid tumors treated with immune checkpoint inhibitors. Cancers (Basel)
2019; 11: 1713.
-
(
PeriMBotteriEPisaE, et al
A single-institution retrospective analysis of metachronous and synchronous metastatic bronchial neuroendocrine tumors. J Thorac Dis
2018; 10: 3928–3939.30174834)
PeriMBotteriEPisaE, et al
A single-institution retrospective analysis of metachronous and synchronous metastatic bronchial neuroendocrine tumors. J Thorac Dis
2018; 10: 3928–3939.30174834
PeriMBotteriEPisaE, et al
A single-institution retrospective analysis of metachronous and synchronous metastatic bronchial neuroendocrine tumors. J Thorac Dis
2018; 10: 3928–3939.30174834,
PeriMBotteriEPisaE, et al
A single-institution retrospective analysis of metachronous and synchronous metastatic bronchial neuroendocrine tumors. J Thorac Dis
2018; 10: 3928–3939.30174834
-
Cho-Hao
Lee,
Chin
Lin,
Chieh-Yung
Wang,
Tzu-Chuan
Huang,
Yi-Ying
Wu,
W.
Chien,
Jia-Hong
Chen
(2018)
Premorbid BMI as a prognostic factor in small-cell lung cancer—a single institute experience
Oncotarget, 9
-
(
FrühMDe RuysscherDPopatS, et al
Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol
2013; 24(Suppl. 6): vi99–105.)
FrühMDe RuysscherDPopatS, et al
Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol
2013; 24(Suppl. 6): vi99–105.
FrühMDe RuysscherDPopatS, et al
Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol
2013; 24(Suppl. 6): vi99–105.,
FrühMDe RuysscherDPopatS, et al
Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol
2013; 24(Suppl. 6): vi99–105.
-
L.
Horn,
A.
Mansfield,
A.
Szczesna,
L.
Havel,
M.
Krzakowski,
M.
Hochmair,
F.
Huemer,
G.
Losonczy,
M.
Johnson,
M.
Nishio,
M.
Reck,
T.
Mok,
S.
Lam,
D.
Shames,
Juan
Liu,
B.
Ding,
A.
López-Chávez,
F.
Kabbinavar,
W.
Lin,
A.
Sandler,
Stephen
Liu
(2018)
First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer
The New England Journal of Medicine, 379
-
(
SinghNSinghPSAggarwalAN, et al
Comorbidity assessment using Charlson comorbidity index and simplified comorbidity score and its association with clinical outcomes during first-line chemotherapy for lung cancer. Clin Lung Cancer
2016; 17: 205–213.e1.)
SinghNSinghPSAggarwalAN, et al
Comorbidity assessment using Charlson comorbidity index and simplified comorbidity score and its association with clinical outcomes during first-line chemotherapy for lung cancer. Clin Lung Cancer
2016; 17: 205–213.e1.
SinghNSinghPSAggarwalAN, et al
Comorbidity assessment using Charlson comorbidity index and simplified comorbidity score and its association with clinical outcomes during first-line chemotherapy for lung cancer. Clin Lung Cancer
2016; 17: 205–213.e1.,
SinghNSinghPSAggarwalAN, et al
Comorbidity assessment using Charlson comorbidity index and simplified comorbidity score and its association with clinical outcomes during first-line chemotherapy for lung cancer. Clin Lung Cancer
2016; 17: 205–213.e1.
-
Evaluation of the lung immune prognostic index for prediction of survival and response in patients treated with atezolizumab for NSCLC: pooled analysis of clinical trials
-
M.
Peri,
E.
Botteri,
E.
Pisa,
F.
Marinis,
A.
Ungaro,
F.
Spada,
C.
Grana,
R.
Gasparri,
L.
Spaggiari,
Nicole
Romentz,
G.
Badalamenti,
A.
Russo,
N.
Fazio
(2018)
A single-institution retrospective analysis of metachronous and synchronous metastatic bronchial neuroendocrine tumors.
Journal of thoracic disease, 10 7
-
W.
Travis,
E.
Brambilla,
A.
Nicholson,
Y.
Yatabe,
J.
Austin,
M.
Beasley,
L.
Chirieac,
S.
Dacic,
E.
Duhig,
D.
Flieder,
K.
Geisinger,
F.
Hirsch,
Y.
Ishikawa,
K.
Kerr,
M.
Noguchi,
G.
Pelosi,
C.
Powell,
M.
Tsao,
I.
Wistuba
(2015)
The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 10 9
-
(
LimJHRyuJSKimJH, et al
Gender as an independent prognostic factor in small-cell lung cancer: Inha Lung Cancer Cohort study using propensity score matching. PLoS One
2018; 13: e0208492.30533016)
LimJHRyuJSKimJH, et al
Gender as an independent prognostic factor in small-cell lung cancer: Inha Lung Cancer Cohort study using propensity score matching. PLoS One
2018; 13: e0208492.30533016
LimJHRyuJSKimJH, et al
Gender as an independent prognostic factor in small-cell lung cancer: Inha Lung Cancer Cohort study using propensity score matching. PLoS One
2018; 13: e0208492.30533016,
LimJHRyuJSKimJH, et al
Gender as an independent prognostic factor in small-cell lung cancer: Inha Lung Cancer Cohort study using propensity score matching. PLoS One
2018; 13: e0208492.30533016
-
(
KazandjianDGongYKeeganP, et al
Prognostic value of the lung immune prognostic index for patients treated for metastatic non-small cell lung cancer. JAMA Oncol
2019; 5: 1481–1485.)
KazandjianDGongYKeeganP, et al
Prognostic value of the lung immune prognostic index for patients treated for metastatic non-small cell lung cancer. JAMA Oncol
2019; 5: 1481–1485.
KazandjianDGongYKeeganP, et al
Prognostic value of the lung immune prognostic index for patients treated for metastatic non-small cell lung cancer. JAMA Oncol
2019; 5: 1481–1485.,
KazandjianDGongYKeeganP, et al
Prognostic value of the lung immune prognostic index for patients treated for metastatic non-small cell lung cancer. JAMA Oncol
2019; 5: 1481–1485.
-
L.
Mezquita,
E.
Auclin,
R.
Ferrara,
M.
Charrier,
J.
Remon,
D.
Planchard,
S.
Ponce,
L.
Ares,
L.
Leroy,
C.
Audigier-Valette,
E.
Felip,
Jorge
Zeron-Medina,
P.
Garrido,
S.
Brosseau,
G.
Zalcman,
J.
Mazières,
Caroline
Caramela,
J.
Lahmar,
J.
Adam,
N.
Chaput,
J.
Soria,
B.
Besse
(2018)
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer
JAMA Oncology, 4
-
Masayuki
Okui,
T.
Yamamichi,
A.
Asakawa,
M.
Harada,
M.
Saito,
H.
Horio
(2017)
Prognostic significance of neutrophil–lymphocyte ratios in large cell neuroendocrine carcinoma
General Thoracic and Cardiovascular Surgery, 65
-
(
HornLMansfieldASSzczęsnaA, et al
First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med
2018; 379: 2220–2229.30280641)
HornLMansfieldASSzczęsnaA, et al
First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med
2018; 379: 2220–2229.30280641
HornLMansfieldASSzczęsnaA, et al
First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med
2018; 379: 2220–2229.30280641,
HornLMansfieldASSzczęsnaA, et al
First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med
2018; 379: 2220–2229.30280641
-
(
IshidaSHashimotoISeikeT, et al
Serum albumin levels correlate with inflammation rather than nutrition supply in burns patients: a retrospective study. J Med Invest
2014; 61: 361–368.25264055)
IshidaSHashimotoISeikeT, et al
Serum albumin levels correlate with inflammation rather than nutrition supply in burns patients: a retrospective study. J Med Invest
2014; 61: 361–368.25264055
IshidaSHashimotoISeikeT, et al
Serum albumin levels correlate with inflammation rather than nutrition supply in burns patients: a retrospective study. J Med Invest
2014; 61: 361–368.25264055,
IshidaSHashimotoISeikeT, et al
Serum albumin levels correlate with inflammation rather than nutrition supply in burns patients: a retrospective study. J Med Invest
2014; 61: 361–368.25264055
-
D.
Meyers,
I.
Stukalin,
I.
Vallerand,
R.
Lewinson,
A.
Suo,
M.
Dean,
S.
North,
A.
Pabani,
T.
Cheng,
D.
Heng,
D.
Bebb,
D.
Morris
(2019)
The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors
Cancers, 11
-
(
OuyangXDangYZhangF, et al
Low serum albumin correlates with poor survival in gastric cancer patients. Clin Lab
2018; 64: 239–245.29739107)
OuyangXDangYZhangF, et al
Low serum albumin correlates with poor survival in gastric cancer patients. Clin Lab
2018; 64: 239–245.29739107
OuyangXDangYZhangF, et al
Low serum albumin correlates with poor survival in gastric cancer patients. Clin Lab
2018; 64: 239–245.29739107,
OuyangXDangYZhangF, et al
Low serum albumin correlates with poor survival in gastric cancer patients. Clin Lab
2018; 64: 239–245.29739107
-
K.
Albain,
J.
Crowley,
M.
LeBlanc,
R.
Livingston
(1990)
Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 8 9
-
(
DengMMaXLiangX, et al
Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
Oncotarget
2017; 8: 37200–37207.28380461)
DengMMaXLiangX, et al
Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
Oncotarget
2017; 8: 37200–37207.28380461
DengMMaXLiangX, et al
Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
Oncotarget
2017; 8: 37200–37207.28380461,
DengMMaXLiangX, et al
Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
Oncotarget
2017; 8: 37200–37207.28380461
-
(
MezquitaLAuclinEFerraraR, et al
Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol
2018; 4: 351–357.29327044)
MezquitaLAuclinEFerraraR, et al
Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol
2018; 4: 351–357.29327044
MezquitaLAuclinEFerraraR, et al
Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol
2018; 4: 351–357.29327044,
MezquitaLAuclinEFerraraR, et al
Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol
2018; 4: 351–357.29327044
-
G.
Fucà,
G.
Galli,
M.
Poggi,
G.
Russo,
C.
Proto,
M.
Imbimbo,
R.
Ferrara,
N.
Zilembo,
M.
Ganzinelli,
A.
Sica,
V.
Torri,
M.
Colombo,
Claudio
Vernieri,
A.
Balsari,
F.
Braud,
M.
Garassino,
D.
Signorelli
(2019)
Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors
ESMO Open, 4
-
Xiaobo
He,
Ting
Zhou,
Yun-peng
Yang,
Shaodong
Hong,
J.
Zhan,
Zhihuang
Hu,
W.
Fang,
T.
Qin,
Yuxiang
Ma,
Yuanyuan
Zhao,
Zhibin
Cheng,
Yan
Huang,
Hongyun
Zhao,
Guangwei
Yang,
Li
Zhang
(2015)
Advanced Lung Cancer Inflammation Index, a New Prognostic Score, Predicts Outcome in Patients With Small-Cell Lung Cancer.
Clinical lung cancer, 16 6
-
S.
Cheng,
W.
Evans,
D.
Stys-Norman,
F.
Shepherd
(2007)
Chemotherapy for Relapsed Small Cell Lung Cancer: A Systematic Review and Practice Guideline
Journal of Thoracic Oncology, 2
-
(
RussoARussanoMFranchinaT, et al
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): a large retrospective multicenter study. Adv Ther
2020; 37: 1145–1155.32002809)
RussoARussanoMFranchinaT, et al
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): a large retrospective multicenter study. Adv Ther
2020; 37: 1145–1155.32002809
RussoARussanoMFranchinaT, et al
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): a large retrospective multicenter study. Adv Ther
2020; 37: 1145–1155.32002809,
RussoARussanoMFranchinaT, et al
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): a large retrospective multicenter study. Adv Ther
2020; 37: 1145–1155.32002809
-
Eun
Kim,
Nambeom
Kim,
Young
Kim,
J.
Seo,
I.
Park,
H.
Ahn,
Y.
Jeong,
Jeong
Kim
(2016)
Prognostic Significance of Modified Advanced Lung Cancer Inflammation Index (ALI) in Patients with Small Cell Lung Cancer_ Comparison with Original ALI
PLoS ONE, 11
-
R.
Bremnes,
S.
Sundstrøm,
U.
Aasebø,
S.
Kaasa,
R.
Hatlevoll,
S.
Aamdal
(2001)
The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up.
Lung cancer, 39 3
-
(
HeXZhouTYangY, et al
Advanced lung cancer inflammation index, a new prognostic score, predicts outcome in patients with small-cell lung cancer. Clin Lung Cancer
2015; 16: e165–e171.25922292)
HeXZhouTYangY, et al
Advanced lung cancer inflammation index, a new prognostic score, predicts outcome in patients with small-cell lung cancer. Clin Lung Cancer
2015; 16: e165–e171.25922292
HeXZhouTYangY, et al
Advanced lung cancer inflammation index, a new prognostic score, predicts outcome in patients with small-cell lung cancer. Clin Lung Cancer
2015; 16: e165–e171.25922292,
HeXZhouTYangY, et al
Advanced lung cancer inflammation index, a new prognostic score, predicts outcome in patients with small-cell lung cancer. Clin Lung Cancer
2015; 16: e165–e171.25922292
-
(
GrivennikovSIGretenFRKarinM
Immunity, inflammation, and cancer. Cell
2010; 140: 883–899.20303878)
GrivennikovSIGretenFRKarinM
Immunity, inflammation, and cancer. Cell
2010; 140: 883–899.20303878
GrivennikovSIGretenFRKarinM
Immunity, inflammation, and cancer. Cell
2010; 140: 883–899.20303878,
GrivennikovSIGretenFRKarinM
Immunity, inflammation, and cancer. Cell
2010; 140: 883–899.20303878
-
Xiaojuan
Ouyang,
Y.
Dang,
Fan
Zhang,
Qiaojia
Huang
(2018)
Low Serum Albumin Correlates with Poor Survival in Gastric Cancer Patients.
Clinical laboratory, 64 3
-
(
KimEYKimNKimYS, et al
Prognostic significance of modified Advanced Lung Cancer Inflammation Index (ALI) in patients with small cell lung cancer_ comparison with original ALI. PLoS One
2016; 11: e0164056.27706243)
KimEYKimNKimYS, et al
Prognostic significance of modified Advanced Lung Cancer Inflammation Index (ALI) in patients with small cell lung cancer_ comparison with original ALI. PLoS One
2016; 11: e0164056.27706243
KimEYKimNKimYS, et al
Prognostic significance of modified Advanced Lung Cancer Inflammation Index (ALI) in patients with small cell lung cancer_ comparison with original ALI. PLoS One
2016; 11: e0164056.27706243,
KimEYKimNKimYS, et al
Prognostic significance of modified Advanced Lung Cancer Inflammation Index (ALI) in patients with small cell lung cancer_ comparison with original ALI. PLoS One
2016; 11: e0164056.27706243
-
Yi
Chen,
Kai
Chen,
Xiaoyun
Xiao,
Yan
Nie,
Shaohua
Qu,
C.
Gong,
F.
Su,
E.
Song
(2016)
Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study
BMC Cancer, 16
-
A.
Russo,
M.
Russano,
T.
Franchina,
M.
Migliorino,
G.
Aprile,
G.
Mansueto,
A.
Berruti,
A.
Falcone,
M.
Aieta,
A.
Gelibter,
A.
Russo,
S.
Barni,
M.
Maio,
O.
Martelli,
F.
Pantano,
D.
Iacono,
L.
Calvetti,
S.
Quadrini,
E.
Roca,
E.
Vasile,
M.
Imperatori,
M.
Occhipinti,
A.
Galvano,
F.
Petrelli,
L.
Calabrò,
G.
Pasquini,
S.
Intagliata,
Giuseppina
Ricciardi,
G.
Tonini,
D.
Santini,
V.
Adamo
(2020)
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study
Advances in Therapy, 37
-
(
AlbainKSCrowleyJJLeBlancM, et al
Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol
1990; 8: 1563–1574.2167954)
AlbainKSCrowleyJJLeBlancM, et al
Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol
1990; 8: 1563–1574.2167954
AlbainKSCrowleyJJLeBlancM, et al
Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol
1990; 8: 1563–1574.2167954,
AlbainKSCrowleyJJLeBlancM, et al
Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol
1990; 8: 1563–1574.2167954
-
D.
Brocco,
P.
Marino,
Antonino
Grassandonia
(2019)
From cachexia to obesity: the role of host metabolism in cancer immunotherapy.
Current Opinion in Supportive & Palliative Care
-
Lei
Zhao,
Lai-han
Leung,
Jing
Wang,
Huihui
Li,
Juanjuan
Che,
Lian
Liu,
Xiaojun
Yao,
B.
Cao
(2017)
Association between Charlson comorbidity index score and outcome in patients with stage IIIB-IV non-small cell lung cancer
BMC Pulmonary Medicine, 17
-
(
LeeCHLinCWangCY, et al
Premorbid BMI as a prognostic factor in small-cell lung cancer-a single institute experience. Oncotarget
2018; 9: 24642–24652.29872494)
LeeCHLinCWangCY, et al
Premorbid BMI as a prognostic factor in small-cell lung cancer-a single institute experience. Oncotarget
2018; 9: 24642–24652.29872494
LeeCHLinCWangCY, et al
Premorbid BMI as a prognostic factor in small-cell lung cancer-a single institute experience. Oncotarget
2018; 9: 24642–24652.29872494,
LeeCHLinCWangCY, et al
Premorbid BMI as a prognostic factor in small-cell lung cancer-a single institute experience. Oncotarget
2018; 9: 24642–24652.29872494
-
M.
Früh,
D.
Ruysscher,
S.
Popat,
L.
Crinò,
Solange
Peters,
E.
Felip
(2013)
Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology, 24 Suppl 6
-
(
KalemkerianGP
Staging and imaging of small cell lung cancer. Cancer Imaging
2012; 11: 253–258.22245990)
KalemkerianGP
Staging and imaging of small cell lung cancer. Cancer Imaging
2012; 11: 253–258.22245990
KalemkerianGP
Staging and imaging of small cell lung cancer. Cancer Imaging
2012; 11: 253–258.22245990,
KalemkerianGP
Staging and imaging of small cell lung cancer. Cancer Imaging
2012; 11: 253–258.22245990
-
(
WeberMMFottnerC
Immune checkpoint inhibitors in the treatment of patients with neuroendocrine neoplasia. Oncol Res Treat
2018; 41: 306–312.29742518)
WeberMMFottnerC
Immune checkpoint inhibitors in the treatment of patients with neuroendocrine neoplasia. Oncol Res Treat
2018; 41: 306–312.29742518
WeberMMFottnerC
Immune checkpoint inhibitors in the treatment of patients with neuroendocrine neoplasia. Oncol Res Treat
2018; 41: 306–312.29742518,
WeberMMFottnerC
Immune checkpoint inhibitors in the treatment of patients with neuroendocrine neoplasia. Oncol Res Treat
2018; 41: 306–312.29742518
-
(
SorichMJRowlandAKarapetisCS, et al
Evaluation of the lung immune prognostic index for prediction of survival and response in patients treated with atezolizumab for NSCLC: pooled analysis of clinical trials. J Thorac Oncol
2019; 14: 1440–1446.30999110)
SorichMJRowlandAKarapetisCS, et al
Evaluation of the lung immune prognostic index for prediction of survival and response in patients treated with atezolizumab for NSCLC: pooled analysis of clinical trials. J Thorac Oncol
2019; 14: 1440–1446.30999110
SorichMJRowlandAKarapetisCS, et al
Evaluation of the lung immune prognostic index for prediction of survival and response in patients treated with atezolizumab for NSCLC: pooled analysis of clinical trials. J Thorac Oncol
2019; 14: 1440–1446.30999110,
SorichMJRowlandAKarapetisCS, et al
Evaluation of the lung immune prognostic index for prediction of survival and response in patients treated with atezolizumab for NSCLC: pooled analysis of clinical trials. J Thorac Oncol
2019; 14: 1440–1446.30999110
-
(
ZhangXGuoMFanJ, et al
Prognostic significance of serum LDH in small cell lung cancer: a systematic review with meta-analysis. Cancer Biomark
2016; 16: 415–423.27062698)
ZhangXGuoMFanJ, et al
Prognostic significance of serum LDH in small cell lung cancer: a systematic review with meta-analysis. Cancer Biomark
2016; 16: 415–423.27062698
ZhangXGuoMFanJ, et al
Prognostic significance of serum LDH in small cell lung cancer: a systematic review with meta-analysis. Cancer Biomark
2016; 16: 415–423.27062698,
ZhangXGuoMFanJ, et al
Prognostic significance of serum LDH in small cell lung cancer: a systematic review with meta-analysis. Cancer Biomark
2016; 16: 415–423.27062698
-
(
ZhaoLLeungLHWangJ, et al
Association between Charlson comorbidity index score and outcome in patients with stage IIIB-IV non-small cell lung cancer. BMC Pulm Med
2017; 17: 112.28806935)
ZhaoLLeungLHWangJ, et al
Association between Charlson comorbidity index score and outcome in patients with stage IIIB-IV non-small cell lung cancer. BMC Pulm Med
2017; 17: 112.28806935
ZhaoLLeungLHWangJ, et al
Association between Charlson comorbidity index score and outcome in patients with stage IIIB-IV non-small cell lung cancer. BMC Pulm Med
2017; 17: 112.28806935,
ZhaoLLeungLHWangJ, et al
Association between Charlson comorbidity index score and outcome in patients with stage IIIB-IV non-small cell lung cancer. BMC Pulm Med
2017; 17: 112.28806935
-
Xiuxiu
Zhang,
Mengfei
Guo,
Jinshuo
Fan,
Zhilei
Lv,
Qi
Huang,
Jieli
Han,
Feng
Wu,
Guorong
Hu,
Juanjuan
Xu,
Yang
Jin
(2016)
Prognostic significance of serum LDH in small cell lung cancer: A systematic review with meta-analysis.
Cancer biomarkers : section A of Disease markers, 16 3
-
Pretreatment neutrophil-to-lymphocyte ratio as a survival predictor for small-cell lung cancer
-
Qiao
Yang,
Zihan
Xu,
Xie-Wan
Chen,
Linpeng
Zheng,
Yong-Xin
Yu,
Xianlan
Zhao,
Mingjing
Chen,
Bangyu
Luo,
Jianmin
Wang,
Jianguo
Sun
(2019)
Clinicopathological characteristics and prognostic factors of pulmonary large cell neuroendocrine carcinoma: A large population‐based analysis
Thoracic Cancer, 10
-
M.
Weber,
C.
Fottner
(2018)
Immune Checkpoint Inhibitors in the Treatment of Patients with Neuroendocrine Neoplasia
Oncology Research and Treatment, 41
-
G.
Kalemkerian
(2011)
Staging and imaging of small cell lung cancer
Cancer Imaging, 11
-
Xuan
Hong,
Baohong
Cui,
Meng
Wang,
Zhao-yang
Yang,
L.
Wang,
Qingyong
Xu
(2015)
Systemic Immune-inflammation Index, Based on Platelet Counts and Neutrophil-Lymphocyte Ratio, Is Useful for Predicting Prognosis in Small Cell Lung Cancer.
The Tohoku journal of experimental medicine, 236 4
-
(
TravisWDBrambillaENicholsonAG, et al
The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol
2015; 10: 1243–1260.26291008)
TravisWDBrambillaENicholsonAG, et al
The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol
2015; 10: 1243–1260.26291008
TravisWDBrambillaENicholsonAG, et al
The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol
2015; 10: 1243–1260.26291008,
TravisWDBrambillaENicholsonAG, et al
The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol
2015; 10: 1243–1260.26291008
-
(
HongXCuiBWangM, et al
Systemic immune-inflammation index, based on platelet counts and neutrophil-lymphocyte ratio, is useful for predicting prognosis in small cell lung cancer. Tohoku J Exp Med
2015; 236: 297–304.26250537)
HongXCuiBWangM, et al
Systemic immune-inflammation index, based on platelet counts and neutrophil-lymphocyte ratio, is useful for predicting prognosis in small cell lung cancer. Tohoku J Exp Med
2015; 236: 297–304.26250537
HongXCuiBWangM, et al
Systemic immune-inflammation index, based on platelet counts and neutrophil-lymphocyte ratio, is useful for predicting prognosis in small cell lung cancer. Tohoku J Exp Med
2015; 236: 297–304.26250537,
HongXCuiBWangM, et al
Systemic immune-inflammation index, based on platelet counts and neutrophil-lymphocyte ratio, is useful for predicting prognosis in small cell lung cancer. Tohoku J Exp Med
2015; 236: 297–304.26250537
-
J.
Kargl,
S.
Busch,
Grace
Yang,
Kyoung-Hee
Kim,
M.
Hanke,
H.
Metz,
Jesse
Hubbard,
Sylvia
Lee,
D.
Madtes,
M.
McIntosh,
A.
Houghton
(2017)
Neutrophils dominate the immune cell composition in non-small cell lung cancer
Nature Communications, 8
-
(
SiegelRLMillerKDJemalA
Cancer statistics, 2020. CA Cancer J Clin
2020; 70: 7–30.31912902)
SiegelRLMillerKDJemalA
Cancer statistics, 2020. CA Cancer J Clin
2020; 70: 7–30.31912902
SiegelRLMillerKDJemalA
Cancer statistics, 2020. CA Cancer J Clin
2020; 70: 7–30.31912902,
SiegelRLMillerKDJemalA
Cancer statistics, 2020. CA Cancer J Clin
2020; 70: 7–30.31912902
-
(
YangQXuZChenX, et al
Clinicopathological characteristics and prognostic factors of pulmonary large cell neuroendocrine carcinoma: a large population-based analysis. Thorac Cancer
2019; 10: 751–760.30734490)
YangQXuZChenX, et al
Clinicopathological characteristics and prognostic factors of pulmonary large cell neuroendocrine carcinoma: a large population-based analysis. Thorac Cancer
2019; 10: 751–760.30734490
YangQXuZChenX, et al
Clinicopathological characteristics and prognostic factors of pulmonary large cell neuroendocrine carcinoma: a large population-based analysis. Thorac Cancer
2019; 10: 751–760.30734490,
YangQXuZChenX, et al
Clinicopathological characteristics and prognostic factors of pulmonary large cell neuroendocrine carcinoma: a large population-based analysis. Thorac Cancer
2019; 10: 751–760.30734490
-
J.
Lim,
J.
Ryu,
Jae
Kim,
Hyun-Jung
Kim,
Dae-Hee
Lee
(2018)
Gender as an independent prognostic factor in small-cell lung cancer: Inha Lung Cancer Cohort study using propensity score matching
PLoS ONE, 13
-
Navneet
Singh,
P.
Singh,
A.
Aggarwal,
D.
Behera
(2016)
Comorbidity Assessment Using Charlson Comorbidity Index and Simplified Comorbidity Score and Its Association With Clinical Outcomes During First-Line Chemotherapy for Lung Cancer.
Clinical lung cancer, 17 3
-
Visit SAGE journals online journals.sagepub.com/ home/tam
-
M.
Sorich,
A.
Rowland,
C.
Karapetis,
A.
Hopkins
(2019)
Evaluation of the lung immune prognostic index for prediction of survival and response in patients treated with atezolizumab for non-small cell lung cancer: pooled analysis of clinical trials.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
-
R.
Siegel,
K.
Miller,
A.
Jemal
(2020)
Cancer statistics, 2020
CA: A Cancer Journal for Clinicians, 70
-
S.
Grivennikov,
F.
Greten,
M.
Karin
(2010)
Immunity, Inflammation, and Cancer
Cell, 140
-
(
KarglJBuschSEYangGH, et al
Neutrophils dominate the immune cell composition in non-small cell lung cancer. Nat Commun
2017; 8: 1–11.28232747)
KarglJBuschSEYangGH, et al
Neutrophils dominate the immune cell composition in non-small cell lung cancer. Nat Commun
2017; 8: 1–11.28232747
KarglJBuschSEYangGH, et al
Neutrophils dominate the immune cell composition in non-small cell lung cancer. Nat Commun
2017; 8: 1–11.28232747,
KarglJBuschSEYangGH, et al
Neutrophils dominate the immune cell composition in non-small cell lung cancer. Nat Commun
2017; 8: 1–11.28232747
-
S.
Coffelt,
M.
Wellenstein,
K.
Visser
(2016)
Neutrophils in cancer: neutral no more
Nature Reviews Cancer, 16
-
S.
Tortorici,
S.
Corrao,
G.
Natoli,
P.
Difalco
(2016)
Prevalence and distribution of oral mucosal non-malignant lesions in the western Sicilian population.
Minerva stomatologica, 65 4
-
(
CoffeltSBWellensteinMDde VisserKE
Neutrophils in cancer: neutral no more. Nat Rev Cancer
2016; 16: 431–446.27282249)
CoffeltSBWellensteinMDde VisserKE
Neutrophils in cancer: neutral no more. Nat Rev Cancer
2016; 16: 431–446.27282249
CoffeltSBWellensteinMDde VisserKE
Neutrophils in cancer: neutral no more. Nat Rev Cancer
2016; 16: 431–446.27282249,
CoffeltSBWellensteinMDde VisserKE
Neutrophils in cancer: neutral no more. Nat Rev Cancer
2016; 16: 431–446.27282249
-
(
BremnesRMSundstromSAasebøU, et al
The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer
2003; 39: 303–313.12609569)
BremnesRMSundstromSAasebøU, et al
The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer
2003; 39: 303–313.12609569
BremnesRMSundstromSAasebøU, et al
The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer
2003; 39: 303–313.12609569,
BremnesRMSundstromSAasebøU, et al
The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer
2003; 39: 303–313.12609569
-
(
BroccoDDi MarinoPGrassandoniaA
From cachexia to obesity: the role of host metabolism in cancer immunotherapy. Curr Opin Support Palliat Care
2019; 13: 305–310.31389842)
BroccoDDi MarinoPGrassandoniaA
From cachexia to obesity: the role of host metabolism in cancer immunotherapy. Curr Opin Support Palliat Care
2019; 13: 305–310.31389842
BroccoDDi MarinoPGrassandoniaA
From cachexia to obesity: the role of host metabolism in cancer immunotherapy. Curr Opin Support Palliat Care
2019; 13: 305–310.31389842,
BroccoDDi MarinoPGrassandoniaA
From cachexia to obesity: the role of host metabolism in cancer immunotherapy. Curr Opin Support Palliat Care
2019; 13: 305–310.31389842
-
(
FucàGGalliGPoggiM, et al
Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. ESMO Open
2019; 4: e000457.30964126)
FucàGGalliGPoggiM, et al
Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. ESMO Open
2019; 4: e000457.30964126
FucàGGalliGPoggiM, et al
Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. ESMO Open
2019; 4: e000457.30964126,
FucàGGalliGPoggiM, et al
Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. ESMO Open
2019; 4: e000457.30964126
-
(
TortoriciSCorraoSNatoliG, et al
Prevalence and distribution of oral mucosal non-malignant lesions in the western Sicilian population. Minerva Stomatol
2016; 65: 191–206.27374359)
TortoriciSCorraoSNatoliG, et al
Prevalence and distribution of oral mucosal non-malignant lesions in the western Sicilian population. Minerva Stomatol
2016; 65: 191–206.27374359
TortoriciSCorraoSNatoliG, et al
Prevalence and distribution of oral mucosal non-malignant lesions in the western Sicilian population. Minerva Stomatol
2016; 65: 191–206.27374359,
TortoriciSCorraoSNatoliG, et al
Prevalence and distribution of oral mucosal non-malignant lesions in the western Sicilian population. Minerva Stomatol
2016; 65: 191–206.27374359
-
(
ChengSEvansWKStys-NormanD, et al
Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol
2007; 2: 348–354.17409809)
ChengSEvansWKStys-NormanD, et al
Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol
2007; 2: 348–354.17409809
ChengSEvansWKStys-NormanD, et al
Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol
2007; 2: 348–354.17409809,
ChengSEvansWKStys-NormanD, et al
Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol
2007; 2: 348–354.17409809
-
Soshi
Ishida,
I.
Hashimoto,
T.
Seike,
Yoshiro
Abe,
Y.
Nakaya,
H.
Nakanishi
(2014)
Serum albumin levels correlate with inflammation rather than nutrition supply in burns patients: a retrospective study.
The journal of medical investigation : JMI, 61 3-4
-
(
ChenYChenKXiaoX, et al
Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study. BMC Cancer
2016; 16: 320.27198767)
ChenYChenKXiaoX, et al
Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study. BMC Cancer
2016; 16: 320.27198767
ChenYChenKXiaoX, et al
Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study. BMC Cancer
2016; 16: 320.27198767,
ChenYChenKXiaoX, et al
Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study. BMC Cancer
2016; 16: 320.27198767